Global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021
Several vendors are offering off-label drugs that belong to different drug classes such as SSRIs (fluvoxamine, paroxetine, sertraline, and fluoxetine) and PDE5 inhibitors (Cialis, VIAGRA, and Levitra). Technavio’s market research report identifies that the increasing application of off-label drugs will be one of the primary growth drivers for the global premature ejaculation treatment market till 2021.
Download free PDF sample copy @ https://goo.gl/g5U7yD
The treatment with off-label drugs belonging to SSRIs has revolutionized the treatment approach for premature ejaculation. In addition, drugs in this class exhibits high efficacy with minor side effects. For instance, people going through the premature ejaculation treatment are administered with paroxetine 20-40 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, and clomipramine 10-50 mg. Global market research analysts predict that this market will grow at a CAGR of close to 9% by 2021.
The premature ejaculation treatment is witnessing growth in the Americas due to the rising number of premature ejaculation cases. The changing lifestyle of people in the Americas is resulting in psychological strain and stress, which in turn, causes premature ejaculation issues. The market will continue to grow in the region throughout the predicted period because a large number of major vendors are headquartered in the Americas.